J Clin Neurol.  2020 Jan;16(1):160-162. 10.3988/jcn.2020.16.1.160.

Refractory Digital Ulcers Treated by Botulinum Toxin and Endothelin Receptor-1 Antagonist in Anti-MDA5-Antibody-Positive Dermatomyositis

Affiliations
  • 1Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea.
  • 2Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
  • 3Department of Pathology, Seoul National University Hospital, Seoul University College of Medicine, Seoul, Korea.
  • 4Department of Neurology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. kyominchoi@naver.com

Abstract

No abstract available.


MeSH Terms

Botulinum Toxins*
Dermatomyositis*
Endothelins*
Ulcer*
Botulinum Toxins
Endothelins

Figure

  • Fig. 1 Muscle biopsy and dermatologic manifestations of the anti-MDA5-Ab-positive dermatomyositis patient. A: Hematoxylin and eosin staining of the vastus lateralis muscle showed minimal size variations of myofibers and revealed some atrophic myofibers (arrows) in the perifascicular area. There was no inflammatory cell infiltration in the endomysium or blood vessels (scale bar: 200 µm). B: Ultrastructurally, tubuloreticular cytoplasmic inclusions were found in endothelial cells (uranyl acetate and lead citrate stain, scale bar: 500 nm). C: Baseline multiple digital ulcers on the right second finger. D: Applying oral bosentan and botulinum toxin injection resulted in the digital ulcers improving at 12 weeks after the first injection of botulinum toxin.


Reference

1. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018; 17:816–828.
2. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011; 65:25–34.
Article
3. Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep. 2010; 12:198–203.
Article
4. Abe Y, Matsushita M, Tada K, Yamaji K, Takasaki Y, Tamura N. Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology (Oxford). 2017; 56:1492–1497.
Article
5. Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology (Oxford). 2017; 56:14–25.
Article
6. Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016; 43:56–62.
Article
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr